Regentis Biomaterials (RGNT) is trading down at $1.73 (-6.76%), as of the latest quote. It operates in the Health Care sector.
| FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|
| Income statement | |||
| Operating income | −$1.93M | $932.0K | −$6.97M |
| Net income | −$4.13M | $4.80M | −$13.6M |
| EPS (diluted) | −$24.09 | $1.72 | −$24.16 |
| Balance sheet | |||
| Cash and equivalents | — | — | $7.38M |
| Total assets | — | $482.0K | $7.62M |
| Total liabilities | — | $6.49M | $2.87M |
| Shareholders' equity | −$45.9M | −$41.1M | $4.74M |
| Cash flow | |||
| Operating cash flow | −$1.22M | −$641.0K | −$1.38M |
From Regentis Biomaterials's 20-F filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. Filings on SEC EDGAR →
No recent news mentioning Regentis Biomaterials in our feed yet.